Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)

被引：16

作者：

Jarque, I. ^{[1
]}

Tormo, M. ^{[2
]}

Bello, J. L. ^{[3
]}

Rovira, M. ^{[4
]}

Batlle, M. ^{[5
]}

Julia, A. ^{[6
]}

Tabares, S. ^{[7
]}

Rivas, C. ^{[8
]}

Fernandez-Sevilla, A. ^{[9
]}

Garcia-Boyero, R. ^{[10
]}

Deben, G. ^{[11
]}

Gonzalez-Campos, J. ^{[12
]}

Capote, F. J. ^{[13
]}

Sanz, M. A. ^{[1
]}

机构：

[1] Univ Hosp La Fe, Valencia 46026, Spain

[2] Hosp Clin Univ, Valencia, Spain

[3] Complejo Hosp Univ, Santiago De Compostela, Spain

[4] Hosp Clin Barcelona, Barcelona, Spain

[5] Hosp Badalona Germans Trias & Pujol, Badalona, Spain

[6] Hosp Gen Valle Hebron, Barcelona, Spain

[7] Hosp Reina Sofia, Cordoba, Spain

[8] Hosp Gen Univ Alicante, Alicante, Spain

[9] Inst Catala Oncol, Barcelona, Spain

[10] Gen Hosp, Castellon de La Plana, Spain

[11] Hosp Juan Canalejo, Coruna, Spain

[12] Hosp Univ Virgen del Rocio, Seville, Spain

[13] Hosp Univ Puerta Mar, Cadiz, Spain

来源：

MEDICAL MYCOLOGY | 2013年 / 51卷 / 02期

关键词：

Caspofungin; invasive fungal disease; hematological patient; candidemia; aspergillosis; CANDIDA-KRUSEI INFECTION; IMMUNOCOMPROMISED PATIENTS; ECHINOCANDINS; ASPERGILLOSIS; EPIDEMIOLOGY; THERAPY;

D O I：

10.3109/13693786.2012.693213

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Caspofungin is an echinocandin with proven efficacy in invasive candidiasis (IC) and invasive aspergillosis (IA). This multicenter, prospective, non-comparative, observational ProCAS study was aimed to assess the effectiveness and safety of caspofungin in adult hematological patients with IC or IA under everyday clinical conditions. Favorable outcomes included complete and partial responses on the last day of caspofungin therapy. Safety was assessed up to 14 days post-caspofungin. A total of 115 patients (69 male) with a median age of 52 years (range, 23-78 years) were analyzed. Underlying disease was acute myeloid leukemia in 45 patients (39%), and 21 (18%) were allogeneic stem cell transplant recipients. Thirty-four (29.5%) patients had a diagnosis of IA and 26 (22.6%) had IC (candidemia). The median duration of caspofungin therapy was 14 days (range, 1-100). The overall favorable response rate was 77% (20/26) for patients with IC (69% first-line) and 79% (27/34) for those with IA. Antifungal therapy with caspofungin was generally well tolerated, only two (1.7%) patients having a non-serious drug-related adverse reaction. These results suggest that caspofungin, either alone or in combination, should be considered an effective and safe option for the treatment of invasive mycoses in patients with severe hematological disorders.

引用

页码：150 / 154

页数：5

共 20 条

[1] Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].